By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) To Officially Launch "Chocola BB Rich Ceramide" In Stores Nationwide 10/13/2016 11:12:13 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Availability Of Once-Daily BELVIQ XR (Lorcaserin Hcl) Extended-Release Tablets 10/3/2016 6:59:20 AM
New Halaven (eribulin) And Lenvima (Lenvatinib) Data To Be Presented At ESMO Demonstrate Continued Commitment To Eisai Inc. (ESALF.PK) Oncology Portfolio 9/29/2016 11:51:43 AM
Eisai Inc. (ESALF.PK) Release: Now Enrolling: Global Phase 3 Clinical Trial To Evaluate Potential First-Line Use Of Lenvatinib In Combination With Pembrolizumab Or Everolimus For Patients With Advanced Renal Cell Carcinoma 9/29/2016 9:37:16 AM
Eisai Inc. (ESALF.PK) Submits Supplemental Application To FDA For Use Of Its Antiepileptic Drug FYCOMPA (Perampanel) As Monotherapy For The Treatment Of Partial Onset Seizures 9/27/2016 6:53:26 AM
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016 8:03:25 AM
Eisai Inc. (ESALF.PK) Highlights Its Strong Pipeline And Innovative Approach To R&D At Company's U.S. Scientific Day 6/30/2016 8:36:22 AM
Eisai Inc. (ESALF.PK) To Present Analyses At 2016 ASCO Annual Meeting From Trials Supporting Recent FDA Approvals For The Company's Oncology Therapies 5/24/2016 8:02:54 AM
Maria Garrigan Appointed Vice President, Global Regulatory Strategy, Oncology Business Group At Eisai Inc. (ESALF.PK) 5/24/2016 6:40:59 AM
Eisai Inc. (ESALF.PK) Announces FDA Approval Of FYCOMPA (Perampanel) Oral Suspension For Adjunctive Therapy In The Treatment Of Partial-Onset Seizures And Primary Generalized Tonic-Clonic Seizures 5/2/2016 6:17:44 AM